On June 4, 2018 Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, reported a key poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2018 Annual Meeting (Press release, Oncolytics Biotech, JUN 4, 2018, View Source [SID1234527183]). The meeting takes place from June 1 – 5, 2018 at McCormick Place, Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These results demonstrate that pelareorep promotes the expression of gene signatures predictive of a response to immunotherapy in breast cancer and hepatocellular carcinoma." said Matt Coffey, President and CEO of Oncolytics Biotech. "The tumor inflammation promoting effects in breast cancer models provide a compelling explanation for the significant overall survival benefit in hormone receptor positive metastatic breast cancer patients in our phase 2, IND 213, study and we believe this will continue to drive interest in our breast cancer program."
Highlights of the poster include:
• Pelareorep promotes expression of gene signatures that are predictive of response to checkpoint inhibitors in select cell lines
• HCC – hepatocellular carcinoma
• HR+ BC – hormone receptor positive breast cancer
• Pronounced tumor inflammatory effects of pelareorep in HR+ BC cells may explain the prominent increase in overall survival in a previous phase 2 randomized clinical study in HR+ mBC patients treated with pelareorep and may render this large breast cancer population susceptible to conventional immunotherapy regimes
• Results warrant further investigation of pelareorep in combination with checkpoint inhibitors
Presenter & Lead Author: Grey A. Wilkinson PhD, Oncolytics Scientist, Translational Medicine
Presentation Title: Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy
Session Title: Developmental Therapeutics – Immunotherapy
Location: McCormick Place: Hall A
Abstract number: 3089
Poster Board #: 303
Date/Time: 6/4/2018; 8:00 AM-11:30 AM
The complete poster can be found online on the company website at View Source
About REOLYSIN/Pelareorep
REOLYSIN, also known as pelareorep, is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.